A metal processor covered here would appear to justify a much higher rating, while cash flow concerns continue to cast a shadow over a once popular litigation funder. Read on here for more on these and other stories.
The news that Pfizer and Germany’s BioNTech have made progress with a Covid-19 vaccine saw stock markets soar, although not all stocks rose, with some beneficiaries of the pandemic, notably small UK biotech stocks, falling sharply, as many clearly think their glory days will soon be coming to an end.
This seems somewhat premature to us, with plenty of work ahead before the vaccine becomes available to everyone and many biotech companies still likely to be…
Sign up and read the full article
Register to continue reading our content.
Get FREE access now
Already a member? Login
Previous article
Next article
More on James Cropper
21/06/2022 · Company Insights
Don’t be fooled by the 175 year history, this elderly business has a reputation for innovation…
24/03/2022 · Company Insights
An acquirer of companies in the scientific instruments sector has reported yet more impressive results. There…
More on Jubilee Metals Group
22/02/2021 · Company Insights
Are we on the verge of a new commodity supercycle, including gold and silver copper and…
10/11/2020 · Company Insights
A metal processor covered here would appear to justify a much higher rating, while cash flow…
More on Manolete Partners PLC
23/06/2022 · Company Insights
Results and updates covered here include yet more disappointment for shareholders of online wine retailer Naked…
12/11/2020 · Company Insights
Our coverage here includes several modestly valued companies whose shares should recover strongly when the world…
More on Zoo Digital
26/01/2022 · Company Insights
This innovative med tech company has secured much needed funding to get it through the sale…
14/12/2021 · Company Insights
While AIM has many exciting companies, it’s rare to find a true global leader like the…
More Company Insights
A mature AIM business growing very strongly
Dividends are poor compensation for declining capital returns
Several large companies leave AIM - more to follow?
More on James Cropper
More on Jubilee Metals Group
More on Manolete Partners PLC
More on Zoo Digital
More Company Insights